A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients

This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants. The primary hypothesis is that administration of grazoprevir for 7 days is sufficiently safe and well tolerated in HCV-infected males.

Inclusion Criteria:

• Baseline health is stable.
• Has a clinical diagnosis of chronic HCV infection.

Exclusion Criteria:

• Has a history of stroke or chronic seizures.
• Has a history of cancer.
• Has a history of human immunodeficiency virus (HIV) infection.
• Has had major surgery, donated blood or participated in another investigational study within the past 3 months.